Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases.
Kyverna Therapeutics has raised $60.0M in total funding. The most recent round was Series B. The last funding was announced in August 2023.
Kyverna Therapeutics's investors include Insight Partners, RTW Investments, Gilead Sciences, Vida Ventures, Intellia Therapeutics.
Kyverna Therapeutics is headquartered in Berkeley, United States.
Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases.
Kyverna Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kyverna Therapeutics — Funding & Investors." VCBacked, August 3, 2023, https://www.vcbacked.co/company/kyverna-therapeutics. Accessed October 29, 2026.
VCBacked. (2023). Kyverna Therapeutics — Funding & Investors. Retrieved October 29, 2026, from https://www.vcbacked.co/company/kyverna-therapeutics
{{cite web |title=Kyverna Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/kyverna-therapeutics |website=VCBacked |access-date=October 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated